Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities... Show more
CME Group maintains a commanding position as the world's largest derivatives marketplace, spanning interest rates, equities, FX, energy, agriculture, and metals. It holds approximately 35-40% of global exchange-traded derivatives volume and dominates U.S. Treasury futures with nearly 90% market share. The company's competitive moat is reinforced by deep liquidity pools, benchmark products like SOFR futures, and capital efficiencies generating over $80 billion in daily margin savings for clients. Innovations such as micro contracts across asset classes and OTC alternatives command premium fees (3-4x standard rates). A partnership with Google Cloud accelerates technology adoption, including AI-driven risk management and cloud migration for scalable infrastructure. Retail participation has surged, with the customer base quadrupling over the past decade, supported by 130+ global brokers. Medium-term, focus on non-U.S. growth (47% of recent ADV) and new asset classes like battery metals and carbon positions CME Group to capture evolving industry demands, though rivals like ICE and emerging fintechs challenge niche segments.
The Q1 2026 earnings release on April 22 offers a critical snapshot of volume momentum, with analysts forecasting $1.91 billion in revenue and testing sustained volatility benefits. Key product rollouts include 24/7 crypto futures and options launching May 29, tapping rising institutional adoption, and Eris SOFR Swap Options on June 16 for enhanced fixed income hedging. Later in 2026, CME Securities Clearing (CMESC) will introduce central clearing for U.S. Treasuries and repos, promising operational efficiencies and expanded margin offsets. Fee adjustments effective April 2026 are projected to boost total revenue by 1.0-1.5% on similar activity levels. On the analyst front, Piper Sandler recently raised its price target to $329 while maintaining Overweight, reflecting optimism amid 19 analysts' average target of $318. These catalysts could shift sentiment if volumes and adoption exceed expectations.
Derivatives trading thrives on volatility, a core driver for CME Group's ADV across interest rates (SOFR, Treasuries), equities, and commodities. Persistent uncertainty from interest rate paths, inflation moderation, and geopolitical tensions—such as U.S. LNG export surges doubling capacity by 2029—bolsters energy and FX volumes. A potential Federal Reserve pivot could amplify SOFR activity, while crypto regulatory clarity accelerates 24/7 trading uptake. Asia-Pacific's rising middle class and 60% contribution to global growth fuel non-U.S. demand (10% CAGR). Conversely, subdued volatility or trade frictions could pressure transaction fees, which comprise the bulk of revenue. Technology shifts toward tokenization and AI risk tools align with CME's Google collaboration, enhancing resilience in a digitizing landscape.
Tickeron’s Trend Prediction Engine is an AI-powered forecasting tool that assists traders in identifying whether a stock, ETF, or other asset is likely to trend bullish, bearish, or sideways over the next week or month. By analyzing vast datasets and pattern recognition, it helps users detect emerging trends, potential breakouts or reversals, and provides predictions across thousands of tradable instruments. The engine features searchable prediction categories, historical performance context, and customizable alerts to enable proactive decision-making. Ideal for navigating volatile markets like derivatives, it empowers investors with data-driven insights for enhanced trading strategies. Explore the Trend Prediction Engine today to stay ahead of market movements.
Consensus projects FY2026 EPS at $12.38-$12.90, reflecting 10%+ growth from 2025, fueled by record ADV trends and non-transaction revenue (8% CAGR in market data). CMESC launch and crypto expansion target margin-accretive clearing volumes, while Google Cloud efficiencies promise neutral-to-positive returns from 2026. Long-term themes include Asia-Pacific dominance, energy transition products (battery metals, carbon), and OTC premium suites. Capital allocation prioritizes 50-60% cash earnings payout via dividends and $3 billion buybacks, with $4.6 billion cash reserves. Competitive threats from fintechs and regulatory scrutiny on clearing mandates warrant monitoring, but CME's liquidity network and product breadth support sustained leadership through 2027 and beyond.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
an operator of securities and commodity exchanges
Industry FinancialPublishingServices
A.I.dvisor indicates that over the last year, CME has been loosely correlated with CBOE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if CME jumps, then CBOE could also see price increases.
| Ticker / NAME | Correlation To CME | 1D Price Change % | ||
|---|---|---|---|---|
| CME | 100% | -1.78% | ||
| CBOE - CME | 59% Loosely correlated | -1.13% | ||
| TW - CME | 45% Loosely correlated | +2.21% | ||
| ICE - CME | 41% Loosely correlated | -0.51% | ||
| MKTX - CME | 35% Loosely correlated | +3.16% | ||
| NDAQ - CME | 29% Poorly correlated | +1.17% | ||
More | ||||
| Ticker / NAME | Correlation To CME | 1D Price Change % |
|---|---|---|
| CME | 100% | -1.78% |
| Financial Publishing/Services industry (15 stocks) | 19% Poorly correlated | +2.35% |
| Commercial Services industry (97 stocks) | 8% Poorly correlated | +1.67% |
CME may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 36 cases where CME's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CME advanced for three days, in of 339 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved below the 0 level on June 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CME as a result. In of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CME turned negative on June 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
CME moved below its 50-day moving average on May 20, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CME declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CME entered a downward trend on June 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.329) is normal, around the industry mean (4.983). P/E Ratio (20.922) is within average values for comparable stocks, (23.876). CME's Projected Growth (PEG Ratio) (4.299) is very high in comparison to the industry average of (1.907). CME has a moderately high Dividend Yield (0.046) as compared to the industry average of (0.021). CME's P/S Ratio (13.106) is slightly higher than the industry average of (7.633).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.